Pharmacogenomics Market Intelligence: Size, Share and Growth Outlook Through 2035

Market Overview

Size, labeling, and commercial frame

• Brevintel analysis values the pharmacogenomics market at USD 5.7 billion in 2025 ($5.7B) and USD 15.4 billion by 2035 ($15.4B).
• Headline cards list 11.16% CAGR, while the narrative outlook cites 10.6% from 2026-2035, also referenced as a 10.61% growth trajectory.
• An intermediate reading places the market at USD 6.2 billion in 2026, and the 2025 estimate is also recorded as USD 5,684.36 million.
• The FDA Table of Pharmacogenomic Biomarkers identified pharmacogenomic information in the labeling of 676 therapeutic products as of March 2026.
• CPIC's 2025 update describes 28 guidelines across 34 genes and 164 drugs, alongside more than 80,000 monthly API queries.
• Thermo Fisher Scientific led with over 16% market share in 2025; the top five held a combined 53.5%.
• Brevintel analysis of Q1 2026 primary research with 280 clinical laboratory directors in 12 North American and European countries found that 67% reported AI-assisted interpretation reduced per-report analytical turnaround by more than 30% versus manual review.
• Uptake was highest at academic medical centers processing more than 500 PGx panels monthly, indicating interpretive capacity is a binding constraint for high-volume programs.

Testing economics and disease mix

• NHGRI documents the decline in human genome sequencing costs from more than USD 1 million in 2007; the subsequent trajectory supports approximately USD 200 per genome for high-throughput sequencing in 2024, based on May 2023 data.
• Sequencing accounted for 43.45% of 2025 technology revenue, while PCR posts the fastest technology CAGR at 10.97%.
• Oncology is the largest disease-area segment at 32.09%, followed by cardiovascular diseases at 24.18%.
• Neurological diseases, at 17.78%, have the highest projected disease-area CAGR of 11.16%.
• Infectious diseases represent 14.08%, mental health 6.29%, and other disease areas 5.59%.
• The addressable market combines laboratory testing with the interpretive layer that turns a genotype into a prescribing decision.
• Adoption is moving beyond a test ordered for one immediate medication decision toward preemptive panels retained in clinical systems and queried at later prescribing events.
• That model raises the value of broad panels and decision support, shifting the operating constraint toward interpretation, workflow integration, and reimbursement rather than assay availability alone.

Market Dynamics

Clinical and economic drivers

• Precision medicine demand is translating into operational demand because drug labeling and clinical guidelines give institutions a basis for selecting patients, drugs, and doses.
• The FDA biomarker-labeling inventory and CPIC guideline infrastructure reduce the evidentiary distance between a genotype result and a prescribing action.
• This favors panel designs that cover multiple actionable genes over one-off tests, particularly when institutions intend to reuse results across therapeutic episodes.
• The World Health Organization identifies adverse drug reactions as a leading cause of morbidity and mortality and notes that up to 60% may be preventable (June 2018).
• Pharmacogenomics can identify inherited variation relevant to drug metabolism or toxicity before exposure where a result changes a defined prescribing pathway.
• Oncology represents 32.09% of 2025 market revenue, and cardiovascular diseases account for 24.18%; both involve medications for which genotype may affect efficacy, safety, or dosing.
• In development programs, the EMA good pharmacogenomic practice framework connects genomic evidence to medicine development and evaluation rather than treating pharmacogenomics solely as a post-launch service.
• Technology economics are expanding the feasible testing mix: sequencing supports broad discovery and multi-gene characterization, while PCR remains attractive when a defined set of variants must be processed quickly and economically.

Coverage, interpretation, and implementation constraints

• Coverage policy remains the principal friction between clinical plausibility and scaled utilization.
• A multi-gene panel can create value over several future prescriptions, but payment decisions are often made against the immediate indication and documented actionability of a single encounter.
• That mismatch can slow adoption even where guidelines exist, especially in systems that lack a reimbursement route for preemptive testing.
• A genotype result requires phenotype translation, consideration of co-medications and clinical context, and delivery in a form a prescriber can use.
• CPIC guidelines supply a standardized reference point, but they do not remove the implementation burden of embedding recommendations within local laboratory and clinical workflows.
• Brevintel analysis indicates that the market's central tension is not a shortage of actionable pharmacogenes, but the gap between evidence availability and routinized payment and prescribing workflows.
• Vendors and service providers that package assay, annotation, and clinical decision support can make panel expansion operationally credible, whereas lower-cost testing without a prescriber-ready output may struggle to move beyond episodic use.
• This distinction also explains why the services segment is expected to grow at 10.83%, slightly faster than products at 10.50%.

Segmentation Analysis

Offering

• Products account for 67.03% of 2025 revenue and are forecast to grow at 10.50%.
• Kits and reagents generate repeat demand as laboratories process panels, while instruments define throughput, automation, and the assays that can be run in-house.
• Services account for 32.97% and grow at 10.83%.
• Services are positioned to benefit where hospitals and clinics need testing plus interpretation without building a full bioinformatics function.
• Brevintel analysis estimates that the 10.61% growth trajectory reflects compounding institutional adoption rather than a one-time expansion in testing volume.
• The key commercial transition is from selling an isolated assay to supporting a repeatable prescribing workflow.
• Panel breadth, report usability, and integration determine whether a laboratory can convert testing demand into recurring utilization.
• As panels widen, providers that combine validated annotation with decision support can reduce the interpretation burden facing raw-data sellers.

Technology

• Sequencing leads with a 43.45% share, reflecting its utility in broader variant characterization and multi-gene panel design.
• PCR holds 27.09% and has the fastest projected technology growth at 10.97%, consistent with targeted deployment where variant lists and prescribing actions are well specified.
• Microarray represents 17.53%, offering standardized interrogation of predefined loci.
• Other technologies account for 11.94%.
• The technology choice is therefore an economic and clinical-fit decision: breadth and discovery favor sequencing, while high-volume, known-variant workflows can favor PCR.
• Brevintel analysis suggests that segment growth will favor combinations that lower the cost of repeated clinical use, rather than a uniform shift toward the broadest technology.
• Sequencing retains the largest technology position because panel breadth matters, but PCR's 10.97% CAGR signals sustained demand for targeted, scalable workflows.
• The two technologies solve different implementation problems and can coexist within the same health system.

Application

• Personalized medicine is the largest application at 38.63% and the fastest growing at 10.99%.
• Its growth depends on a result being available when a medication decision occurs, which strengthens the case for preemptive panel models.
• Drug discovery and preclinical development comprise 30.33%, where genomic evidence can shape biomarker strategy and development plans under the EMA framework.
• Clinical research represents 19.92%.
• Other applications account for 11.11%.
• Personalized medicine's 10.99% CAGR identifies a direct clinical-deployment route to expansion that requires an actionable result at the point of prescribing.
• The research-and-development route depends on standardized, submission-ready evidence.
• Suppliers able to support both routes with a coherent data and interpretation layer are better insulated from purely instrument- or assay-price competition.

Disease area

• Oncology is the largest disease-area segment at 32.09% of 2025 revenue.
• Cardiovascular diseases follow at 24.18%.
• Neurological diseases, at 17.78%, have the highest projected disease-area CAGR of 11.16%.
• That neurological growth places interpretive quality at a premium because medication-response decisions often involve complex prescribing histories.
• Infectious diseases represent 14.08%.
• Mental health accounts for 6.29%.
• Other disease areas account for 5.59%.
• Both oncology and cardiovascular care involve medications for which genotype may affect efficacy, safety, or dosing, extending demand into distinct clinical pools.

End use

• Hospitals and clinics lead at 37.93%, reflecting their proximity to prescribing decisions.
• Pharmaceutical and biotechnology companies account for 26.57%.
• CROs account for 19.38% while delivering the fastest end-use CAGR at 11.07%.
• Outsourced capabilities can be particularly relevant where sponsors need pharmacogenomic evidence without internalizing every laboratory and analytical capability.
• Academic and research institutions represent 10.11%.
• Other end users account for 6.02%.
• CROs' 11.07% CAGR identifies an outsourced execution route for research and development.
• Health systems can prioritize a clinically interpretable service, while laboratories evaluate whether to retain testing internally through products or outsource analytical and interpretive work.

Regional Outlook

North America and Europe

• North America represents 48.42% of the market in 2025 and is projected to grow at 10.40%.
• North American revenue rises from USD 2,752.11 million in 2025 to USD 7,329.48 million in 2035.
• The U.S. accounts for 91.48% of North American revenue, and Canada accounts for the remaining 8.52%.
• In the U.S., the FDA biomarker-labeling table provides a visible reference for drug-gene relevance.
• Europe holds 26.78% of 2025 revenue and is forecast to grow at 10.78%.
• Germany, France, the UK, Spain, Italy, and the Netherlands are within the regional scope.
• The EMA guideline gives pharmaceutical developers a common regulatory reference for good pharmacogenomic practice.
• The NHS 100,000 Genomes Project pharmacogenomics substudy assessed 76,805 participants across four drug-gene pairs: DPYD, NUDT15, TPMT, and UGT1A1.
• In December 2025, the EMA issued a concept paper on revising the guideline, indicating an ongoing update to the regulatory framework.
• Brevintel analysis views North America's 48.42% share as a function of a deep installed base and explicit biomarker-labeling signals, while Europe's 10.78% CAGR is supported by a common regulatory foundation and large-scale public genomics activity.

Asia Pacific, Latin America, and Middle East & Africa

• Asia Pacific accounts for 20.45% of the market and is the fastest-growing region at 11.01%.
• China, Japan, India, Australia, and South Korea form the stated country scope.
• A 2025 study from the Taiwan Precision Medicine Initiative analyzed pharmacogenomic variation in 486,956 Han Chinese participants.
• That dataset reinforces the importance of population-specific evidence when panels and recommendations are deployed beyond historically European-ancestry datasets.
• This creates a design requirement for laboratories: broad panels and interpretation logic must be validated for the populations they serve, not simply transferred from another region.
• Latin America represents 3.18% of 2025 revenue, covering Brazil, Mexico, and Argentina, with a projected CAGR of 10.19%.
• Middle East & Africa represents 1.18%, including Saudi Arabia, South Africa, and the UAE, with a projected CAGR of 9.38%.
• Their projected CAGRs of 10.19% and 9.38% indicate growth from smaller bases, where affordability, laboratory access, and local clinical decision-support infrastructure weigh more heavily on the pace at which technical capability becomes routine care.
• Asia Pacific's 11.01% CAGR carries a different implication: the region's expansion depends on localization of evidence and workflows.
• Providers that can demonstrate fit across local populations and care settings have a clearer path than suppliers relying on a single-region clinical evidence model.

Competitive Landscape

Structure and implementation problems

• Competition spans integrated product suppliers, reference laboratories, specialist pharmacogenomics providers, and research-service organizations.
• Thermo Fisher Scientific led with over 16% market share in 2025.
• The top five players include Thermo Fisher Scientific, QIAGEN, Illumina Inc., F. Hoffmann-La Roche, and Agilent Technologies, which collectively held 53.5% in 2025.
• Scale providers compete through instruments, assay consumables, automation, and distribution; service-oriented competitors compete through turnaround time, clinical interpretation, and the ability to fit results into prescribing workflows.
• As use shifts toward preemptive, multi-gene testing, interpretive performance and compatibility with clinical systems become as commercially relevant as analytical accuracy.
• Health systems can prioritize a clinically interpretable service, pharmaceutical and biotechnology companies can require development-stage genomic support, and laboratories can choose in-house products or outsourced analysis.
• This prevents a single measure of platform breadth from serving as a universal measure of competitive strength.
• Brevintel analysis of Q1 2026 research with 280 directors in 12 countries found 67% reported more than 30% faster analytical turnaround with AI-assisted interpretation, with uptake highest above 500 PGx panels monthly.

Recent industry developments

• In 2025, CPIC's guideline update described 28 guidelines, 34 genes, and 164 drugs, with its API exceeding 80,000 monthly queries.
• The EMA published its Concept Paper on a revision of the Good Pharmacogenomic Practice guideline in December 2025.
• A 2025 study using Taiwan Precision Medicine Initiative data evaluated pharmacogenomic variation in 486,956 Han Chinese participants.
• The NHS 100,000 Genomes Project pharmacogenomics substudy assessed 76,805 participants across DPYD, NUDT15, TPMT, and UGT1A1.
• Sequencing-cost evidence from May 2023 supports approximately USD 200 per genome in 2024 after a decline from more than USD 1 million in 2007.
• WHO guidance from June 2018 notes that up to 60% of adverse drug reactions may be preventable, supporting a purchasing case where results change a defined pathway.
• FDA labeling covering 676 therapeutic products as of March 2026 continues to widen clinical entry points for pharmacogenomic testing.
• The 2025 estimate of USD 5,684.36 million, paired with the $5.7B / $15.4B path to 2035, underscores that interpretive capacity rather than sequencing alone is becoming the binding condition for scaling high-volume programs.

Integrated producers

• Thermo Fisher Scientific Inc.
• Illumina Inc.
• F. Hoffmann-La Roche Ltd.
• Agilent Technologies Inc.
• Qiagen N.V.
• Danaher Corporation
• Becton Dickinson and Company
• Bio-Rad Laboratories Inc.
• Revvity
• Takara Bio Inc.

Specialty suppliers

• Admera Health
• Genelex
• Genomind
• OneOme
• Labcorp Holdings Inc.
• Eurofins Scientific
• Charles River Laboratories
• Novogene Co. Ltd.